1MK Stock Chart & Stats
€0.06
>-€0.01(-5.00%)
At close: 4:00 PM EST
€0.06
>-€0.01(-5.00%)
Day’s Range― - ―
52-Week Range€0.05 - €0.21
Previous CloseN/A
Volume0.00
Average Volume (3M)4.78K
Market Cap
€21.83M
Enterprise Value€39.82M
Total Cash (Recent Filing)€4.97M
Total Debt (Recent Filing)€12.08M
Price to Earnings (P/E)1.8
Beta0.50
Next Earnings
Apr 22, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding195,260,220
10 Day Avg. Volume14,329
30 Day Avg. Volume4,776
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.65
Price to Sales (P/S)1.55
P/FCF Ratio-3.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)€7.75M
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe sharp 2025 revenue rebound shows that demand for the company’s Cellvizio platform and related offerings can recover after a weak period. If sustained, renewed commercial traction could expand the installed base, increase procedure volumes, and support recurring consumables revenue.
Strong Gross MarginA consistently high gross margin indicates meaningful economic value in the company’s specialized endomicroscopy offering and leaves substantial gross profit available to fund selling, research, and support activities. Maintaining this profile would strengthen the model as revenue scales.
Debt ReductionThe substantial reduction in debt is a constructive balance-sheet change that lowers absolute financing obligations and may reduce future refinancing pressure. Although leverage remains challenging, continued deleveraging would improve financial flexibility and preserve more resources for commercial development.
Bears Say
Deep Operating LossesThe deeply negative operating margin shows that the company’s core activities are not yet covering operating expenses, even after the revenue rebound. This weakens earnings durability and means additional growth must be achieved before improved sales can translate into sustainable operating profitability.
Persistent Cash BurnNegative operating and free cash flow across all reported years indicates that the business continues to consume cash rather than fund itself internally. The 2025 accounting profit therefore did not provide operating liquidity, leaving ongoing reliance on external funding or balance-sheet actions.
Negative Shareholders’ EquityPersistently negative equity reflects accumulated deficits and materially limits financial flexibility. Combined with remaining debt, this weak capital base increases solvency and refinancing risk, while constraining the company’s ability to absorb further losses or invest in expansion without outside support.
MAUNA KEA TECHNOLOGIES News
1MK FAQ
What was MAUNA KEA TECHNOLOGIES’s price range in the past 12 months?
MAUNA KEA TECHNOLOGIES lowest stock price was €0.05 and its highest was €0.21 in the past 12 months.
What is MAUNA KEA TECHNOLOGIES’s market cap?
MAUNA KEA TECHNOLOGIES’s market cap is €21.83M.
When is MAUNA KEA TECHNOLOGIES’s upcoming earnings report date?
MAUNA KEA TECHNOLOGIES’s upcoming earnings report date is Apr 22, 2027 which is in 189 days.
How were MAUNA KEA TECHNOLOGIES’s earnings last quarter?
MAUNA KEA TECHNOLOGIES released its earnings results on Oct 08, 2026. The company reported -€0.026 earnings per share for the quarter.
Is MAUNA KEA TECHNOLOGIES overvalued?
According to Wall Street analysts MAUNA KEA TECHNOLOGIES’s price is currently Overvalued.
Does MAUNA KEA TECHNOLOGIES pay dividends?
MAUNA KEA TECHNOLOGIES does not currently pay dividends.
What is MAUNA KEA TECHNOLOGIES’s EPS estimate?
MAUNA KEA TECHNOLOGIES’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MAUNA KEA TECHNOLOGIES have?
MAUNA KEA TECHNOLOGIES has 195,260,220 shares outstanding.
What happened to MAUNA KEA TECHNOLOGIES’s price movement after its last earnings report?
MAUNA KEA TECHNOLOGIES reported an EPS of -€0.026 in its last earnings report. Following the earnings report the stock price went up 1.754%.
Which hedge fund is a major shareholder of MAUNA KEA TECHNOLOGIES?
Currently, no hedge funds are holding shares in DE:1MK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MAUNA KEA TECHNOLOGIES
Mauna Kea Technologies SA operates as a medical device enterprise, producing and distributing its offerings throughout Europe and worldwide. Its product line serves various medical specialties such as gastroenterology, pulmonology, and urology. Central to its portfolio is Cellvizio, an in vivo cellular imaging platform that delivers real-time data. This innovative system assists medical practitioners in tracking disease evolution, evaluating immediate physiological responses, delineating ambiguous tissue areas, and providing guidance during surgical procedures. Founded in 2000, the company's headquarters are situated in Paris, France.